High telomerase activity and long telomeres in advanced hepatocellular carcinomas with poor prognosis

Telomerase reactivation and telomere maintenance are crucial in carcinogenesis and tumor progression. In this study, the relationships between telomere parameters, chromosomal instability and clinicopathological features were evaluated in hepatocellular carcinomas (HCCs). Telomere length (TL), telomerase activity (TA) and human telomerase reverse transcriptase (hTERT) mRNA levels were measured in 49 hepatitis B virus (HBV)-related HCCs and corresponding non-tumorous tissues. The results were compared with clinicopathological data, including differentiation, multipolar mitosis (MM), anaphase bridge, immunohistochemical stain results for cytokeratin 19 (CK19) and patient outcome. TL of HCCs ranged from 4.7 to 13.1 kb, and 44.4% of HCCs showed telomere lengthening. hTERT mRNA levels and TA were closely related (P=0.008), and were significantly higher in HCCs than non-tumorous tissues. TL was significantly higher in HCCs with strong TA (P=0.048), high hTERT mRNA levels (P=0.001) and poor differentiation (P=0.041). Frequent MM was associated with poor differentiation (P=0.007) and advanced stage (P<0.001). TA was positively correlated with MM, anaphase bridges and advanced stage (P=0.019, P=0.017 and P=0.029). Thirteen (28.3%) HCCs were CK19+ and demonstrated longer telomeres than CK19− HCCs (P=0.046). Overall survival was poor in HCCs with MM >0.4 per field (P=0.016), high TA (P=0.009) and high TL ratio (HCC/non-HCC) >0.8 (P=0.044). Our results show that long telomeres, high TA and high mitotic instability are poor prognostic markers for HBV-related HCCs and their close association suggests that telomere maintenance may be important for the progression of HCCs with high chromosomal instability to more aggressive ones.

[1]  M. Manns,et al.  Hepatocellular telomere shortening correlates with chromosomal instability and the development of human hepatoma , 2004, Hepatology.

[2]  T. Nakajima,et al.  Tumor size-independence of telomere length indicates an aggressive feature of HCC. , 2004, Biochemical and biophysical research communications.

[3]  F. Ishikawa.  Telomere crisis, the driving force in cancer cell evolution. , 1997, Biochemical and biophysical research communications.

[4]  K. Collins.  Mammalian telomeres and telomerase. , 2000, Current opinion in cell biology.

[5]  Axel Hoos,et al.  Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. DePinho,et al.  Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. , 2003, Cancer research.

[7]  Y. N. Park,et al.  Molecular analysis of PinX1 in human hepatocellular carcinoma. , 2004, Oncology reports.

[8]  D. Gisselsson,et al.  Telomere‐mediated mitotic disturbances in immortalized ovarian epithelial cells reproduce chromosomal losses and breakpoints from ovarian carcinoma , 2005, Genes, chromosomes & cancer.

[9]  R. DePinho,et al.  Connecting chromosomes, crisis, and cancer. , 2002, Science.

[10]  E. Montgomery,et al.  Telomere Length Abnormalities Occur Early in the Initiation of Epithelial Carcinogenesis , 2004, Clinical Cancer Research.

[11]  P. Kruk,et al.  DNA damage and repair in telomeres: relation to aging. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[12]  June Corwin,et al.  Telomerase Catalytic Subunit Homologs from Fission Yeast and Human , 1997 .

[13]  T. Roskams.  Liver stem cells and their implication in hepatocellular and cholangiocarcinoma , 2006, Oncogene.

[14]  S. Thorgeirsson,et al.  A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells , 2006, Nature Medicine.

[15]  E. Hiyama,et al.  Telomere and telomerase in stem cells , 2007, British Journal of Cancer.

[16]  J. Lau,et al.  Hepatocellular carcinoma expressing both hepatocellular and biliary markers also expresses cytokeratin 14, a marker of bipotential progenitor cells. , 1999, Journal of hepatology.

[17]  S. Petersen,et al.  hTERT gene dosage correlates with telomerase activity in human lung cancer cell lines. , 2002, Cancer letters.

[18]  Young Nyun Park,et al.  Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis , 2007, Hepatology.

[19]  H. Asakura,et al.  Quantitation of telomerase activity in hepatocellular carcinoma: a possible aid for a prediction of recurrent diseases in the remnant liver. , 1998, Hepatology.

[20]  D. Gisselsson,et al.  Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  T. Tauchi,et al.  Telomeres and telomerase in hematologic neoplasia , 2002, Oncogene.

[22]  J. Fujimoto,et al.  Telomerase activity in hepatocellular carcinoma and adjacent liver tissues , 1998, Journal of surgical oncology.

[23]  T. Ide,et al.  Expression of telomerase component genes in hepatocellular carcinomas. , 2000, European journal of cancer.

[24]  M. Gebel,et al.  Induction of aneuploidy by increasing chromosomal instability during dedifferentiation of hepatocellular carcinoma , 2004 .

[25]  D. Gisselsson,et al.  Centrosomal abnormalities, multipolar mitoses, and chromosomal instability in head and neck tumours with dysfunctional telomeres , 2002, British Journal of Cancer.

[26]  C. Heaphy,et al.  Telomeres: Prognostic markers for solid tumors , 2006, International journal of cancer.

[27]  J. Rutka,et al.  Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Sainger,et al.  Clinical usefulness of telomerase activation and telomere length in head and neck cancer , 2002, Head & neck.

[29]  R. DePinho,et al.  Telomere dysfunction and evolution of intestinal carcinoma in mice and humans , 2001, Nature Genetics.

[30]  D. Gisselsson,et al.  Connecting mitotic instability and chromosome aberrations in cancer--can telomeres bridge the gap? , 2005, Seminars in cancer biology.

[31]  Chanil Park,et al.  Telomere shortening and telomerase reactivation in dysplastic nodules of human hepatocarcinogenesis. , 2003, Journal of hepatology.

[32]  K. Rudolph,et al.  Telomeres and telomerase in cancer stem cells. , 2006, European journal of cancer.

[33]  P. Schirmacher,et al.  Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease. , 2007, Gastroenterology.

[34]  Y. N. Park,et al.  Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype. , 2004, Journal of hepatology.

[35]  M. Benito,et al.  Correlations of telomere length, telomerase activity, and telomeric‐repeat binding factor 1 expression in colorectal carcinoma , 2006, Cancer.

[36]  G. Thomas,et al.  Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. , 2001, Gastroenterology.

[37]  H. Hisatomi,et al.  Telomerase reverse transcriptase mRNA expression and telomerase activity in hepatocellular carcinoma , 1999, Journal of Gastroenterology.

[38]  J. Murnane,et al.  Chromosome rearrangements resulting from telomere dysfunction and their role in cancer , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[39]  F. Ishikawa,et al.  Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas , 1998, Nature Genetics.

[40]  H. Hisatomi,et al.  Levels of telomerase catalytic subunit mRNA as a predictor of potential malignancy. , 1999, International journal of oncology.

[41]  R. Rosenberg,et al.  Prognostic potential of the telomerase subunit human telomerase reverse transcriptase in tumor tissue and nontumorous mucosa from patients with colorectal carcinoma , 2002, Cancer.

[42]  M. Feinmesser,et al.  Telomere length is a prognostic factor in neuroblastoma , 2006, Cancer.

[43]  J. Guillem,et al.  Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  E. Lesaffre,et al.  The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin , 2006, Histopathology.

[45]  S. Kubo,et al.  Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence , 2003, Cancer science.

[46]  Y. N. Park,et al.  Up-regulation of telomere-binding proteins, TRF1, TRF2, and TIN2 is related to telomere shortening during human multistep hepatocarcinogenesis. , 2005, The American journal of pathology.

[47]  M. Makuuchi,et al.  Telomerase activity as a predictive marker for recurrence of hepatocellular carcinoma after hepatectomy. , 2001, American journal of surgery.

[48]  D. Yoon,et al.  Expression of biliary antigen and its clinical significance in hepatocellular carcinoma. , 1999, Yonsei medical journal.